top cml conference

[Guest guest]

next weekend there will be a top important cml conference in genoa italy. i am

enclosing the program of the meeting so everyone can read the topics which cover

every aspect of cml today and the names of all the leading drs that will attend

and give presentations. the meeting is organized by ESH (european school of

hematologists) . they have a web site which lists all their activities

www.esh.org

since i thought it will be extremely important for cml patients to hear the

presentations and the data which will be presented i applied to esh and asked to

participate as a cml patient. they approved it and sent me the required forms. i

sent them the registration with the 550 euros fees and made all flight and hotel

arrangments.

sudenly yesterday i recieved an email from esh canceling my participation

claiming that this meetings are open only for hematologists and scitists. i

think it is a shame and no cml meeting should take place if there is no

representation of us, the patients.

here is esh email to me

Dear Sharf Giora

Thank you for having contacted us about our upcoming ESH conference on

chronic myeloid leukaemia to take place in Genoa on November 11-13, 2005.

I hope that you will understand that we cannot register you for this meting

which is reserved for haematologists. Indeed, the European School of

Haematology is an institution for continuing education for clinical doctors

and scientists and we do not as yet have a branch devoted to the education

of patients. As soon as this question arises on our agenda, I will certainly

inform you.

In the meantime, I congratulate you on the important work you are doing for

CML patients.

Kind regards

DiDi Jasmin

Executive Director, ESH

Centre Hayem

H?pital Saint-Louis

Paris 75010, France

Telephone : 33-1 42 06 65 40

Fax: 33-1 42 06 05 87

email : eshdi@...

website : www.esh.org

i will do my best to use my connections and get the most important data from

this meeting but it will not be the same.

here is the program

CML in the 21st Century

11-13 November 2005 - Genoa, Italy

Principal organisers: A. Carella, J. Goldman

Co-organisers: M. Baccarani, R. Hehlmann, F. Guilhot, N. Cross, A. Gewirtz, J.

Melo

..

Friday, 11 November

08.30 PLENARY 1 Chairs:

Goldman/Angelo Carella

Lorenzo Pinna Protein kinases as ‘drugable’ targets in malignant

disease

09.15 PLENARY 2 Chairs: Angelo Carella/ Goldman

Rick A van Etten Unravelling Abl

10.00 Session 1 – Molecular update

Chairs: Alan Gewirtz, Giuseppe Saglio

Junia Melo Regulation of the Bach2 transcription factor by

Bcr-Abl

Nick Cross Tyrosine kinases in CML and related disorders

Giuseppe Saglio Induction of apoptosis as a targeted therapy for CML

patients resistant to imatinib

s Reiter FIP1L1-PDGFRA positive myeloproliferative syndrome

Jim Development of AMN107, a novel second generation

inhibitor of Bcr/Abl

Nick Donato Targets and regulation of Lyn kinase in imatinib sensitive

and resistant CML

Alan Gewirtz Gene silencing strategies for the treatment of

refractory CML

Danilo Perrotti ReSETting PP2A tumor suppressor activity to

antagonize BCR/ABL leukemogenic potential in blast crisis CML

Jeroen Janssen Genes potentially involved in transformation of CML

Enrica Lerma Gene profiling – what answers are possible?

14.00 Session 2 - Genomic instability

Chairs: Skorski, Pierre Laneuville

Wang Abl in the genotoxic response

Tomas Skorski BCR/ABL regulates DNA damage and repair to induce

imatinib resistance and genomic instability

Carroll BCR/ABL Disrupts the response to DNA damage leading

to chromosomal instability

Bruno Calabretta Genetic and epigenetic changes during CML disease

progression

Pierre Laneuville Genomic instability in transgenic mouse models of

bcr/abl

expression

Feyruz Rassool DNA damage and repair infidelity: a model for genomic

instability in myeloid malignancies?

15.30 Session 3 – Stem cells and animal models

Chairs: Junia Melo, Bayard son

Ralph Arlinghaus Suppression of normal hematopoiesis by a modified form

of neutrophil gelatinase-associated lipocalin (NGAL) derived from

BCR-ABL-positive cells

Bayard son Possible strategies for selectively killing Ph+ dormant

stem cells

Connie Eaves Genomic analysis of CML stem cells reveals an altered

transcriptome and hidden mutants

Mhairi Copland Targeting quiescent stem cells

16.30 Session 4 – BCR-ABL anD OTHER THERAPEUTIC TARGETS –

PRECLINICAL

Chairs: Nick Cross, Deininger

von Bubnoff Prediction of resistance mutation patterns for novel Abl

kinase

inhibitors using a cell-based screening strategy

Oliver Hantschel Structure-function analysis on Bcr-Abl

Deininger BCR-ABL kinase domain mutations: beyond imatinib

resistance

Carlo Gambacorti Passerini Conformation dependent binding of SKI-606 to Abl

Shinya Kimura NS-187, a new dual Bcr-Abl/Lyn tyrosine

kinase inhibitor

Tim Br?mmendorf Imatinib plus hypusination inhibitors

Saturday, 12 November

08.30 Session 5 – BCR-ABL AND OTHER THERAPEUTIC STRATEGIES -

CLINICAL

Chairs: Rudiger Hehlmann, Barrett

Moshe Talpaz Dasatinib (BMS-354825) – Clinical results updated

Cortes AMN107 – Clinical results updated

Michele Baccarani Imatinib high dose and imatinib in combination with

interferon

Gert Ossenkoppele HOVON study of imatinib and cytarabine in first chronic

phase CML

Ute Berger Treatment intensification by combination therapies

and dose

escalation: The

German CML-Study IV

Francois Guilhot Rationale of combination of TK with Interferon or

chemotherapy:

Preliminary results of the French trials

Cortes Farnesyl transferase inhibitors in CML: Still a role?

11.30 Session 6 – Immune mechanisms and

immunotherapy

Chairs: Michele Baccarani, Gale

Barrett Immunotherapy strategies with or without

allo-transplants

Jeff Molldrem Unmasking self antigens as

vaccine targets

Scheinberg Specific immunotherapy of CML

Bocchia P210-derived peptide vaccine for minimal residual

disease

in CML

Evaluation of peptide immunization in CML (EPIC

study)

Hans Stauss TCR genes for the therapy of leukaemia

14.00 Session 7 – Molecular monitoring & Abl mutations

Chairs: Tim , Neil Shah

Tim Early predictors of response to ABL kinase inhibitors

s Hochhaus Outcome of patients after detection of BCR-ABL mutations

Marin Long-term BCR-ABL transcript patterns

Neil Shah Not all Abl mutations are ‘equal’

Simona Soverini ABL mutations and resistance to TK inhibitors

Schiffer How should molecular and mutational analyses be used

to advise patients with CML in chronic phase?

16.00 Session 8 – MOLECULAR STANDARDIZATION

Chairs: s Hochhaus, Giovanni elli

Goldman Standardisation – an international perspective

Tim Towards international standardisation for

MRD measurement

in CML

Giovanni elli Molecular standardization in monitoring in

the era

of dual TK inhibitors

s Hochhaus European Proposal on Harmonization of PCR procedures

Sunday, 13 November

08.30 Session 9 – Grafting strategies

Chairs: Alois Gratwohl, Schiffer

Agnes Devergie Allo-SCT in 5000 patients with CML in 1st CP –

The European experience 1995-2002

Jane Apperley Matched unrelated donor SCTs for CML-CP

Alois Gratwohl Do we need allogeneic HSCT in the tyrosine kinase

inhibitor era?

Angelo Carella Long-term survival in CML patients after autografting/IFN-a

and imatinib

11.00 Session 10 – Leukemia-Net & Guidelines

Chair: Francois Guilhot, Silver

Jorg Hasford Prognosis for CML patients

treated with imatinib

Pierre Laneuville Canadian Consensus Guidelines

for CML

R?diger Hehlmann Organization and highlights of the European LeukemiaNet

Bengt Simonsson LeukemiaNet – Current progress

12.30 End of

meeting

i hope that we will be able to get the latest info from our drs and do

something about future participation of patients in such meetings.

shalom

giora

israel